Stock Events

Stock Events

Outlook Therapeutics 

€0.3822
199
+€0.01+2.41% 12:17 Today

Statistics

Day High
0.4124
Day Low
0.3822
52W High
0.5145
52W Low
0.3732
Volume
-
Avg. Volume
-
Mkt Cap
93.05M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Dec 18Expected
Q2 2026
Next
-0.08
-0.07
-0.07
-0.07
Expected EPS
-0.07422136978
Actual EPS
N/A

Financials

-4,542.75%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.2MRevenue
-54.48MNet Income

Analyst Ratings

$4.07Average Price Target
The highest estimate is ⁦7.97⁩.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 41O.XETRA. It's not an investment recommendation.
NVIDIA
24
NVDA
Apple
20
AAPL
Amazon
20
AMZN
Microsoft
17
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals competes in the ophthalmology space, particularly with treatments for eye diseases, directly competing with Outlook Therapeutics' eye therapy products.
Regenxbio
RGNX
Mkt Cap475.29M
REGENXBIO Inc. focuses on the development of gene therapy products for eye diseases, offering direct competition to Outlook Therapeutics' gene therapy approaches for ocular diseases.
Novartis
NVS
Mkt Cap303.67B
Novartis AG has a strong presence in the ophthalmology market, including therapies for macular degeneration and other eye conditions, competing with Outlook Therapeutics.
Bausch Health Companies
BHC
Mkt Cap3.07B
Bausch Health Companies Inc., through its eye health division, provides a wide range of products for eye conditions, directly competing with Outlook Therapeutics.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie, after acquiring Allergan, has become a significant player in the eye care market, offering products that compete with Outlook Therapeutics' treatments.
Rogers
ROG
Mkt Cap2.37B
Roche Holding AG, with its ophthalmology division, offers treatments for various eye diseases, competing with Outlook Therapeutics in the broader eye care market.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. has investments in treatments for eye diseases, including therapies for retinal disorders, making it a competitor to Outlook Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical division, develops treatments for eye health, including surgery and vision care, competing with Outlook Therapeutics.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline plc, with its healthcare portfolio, includes treatments for eye conditions, indirectly competing with Outlook Therapeutics in the healthcare market.

About

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Show More
CEO
Robert Charles Jahr
Employees
17
Country
United States
ISIN
US69012T3059
WKN
000A4046T

Listings

STU
DE
41O.STU
XNAS
US
OTLK
MU
DE
41ON.MU
BOATS
BOATS
OTLK.BOATS

0 Comments

Share your thoughts

FAQs

What is Outlook Therapeutics stock price today?▼
The current price of 41O.XETRA is €0.38 EUR — it has increased by +2.41% in the past 24 hours. Watch Outlook Therapeutics stock price performance more closely on the chart.
What is Outlook Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Outlook Therapeutics stocks are traded under the ticker 41O.XETRA.
What is Outlook Therapeutics market cap?▼
Today Outlook Therapeutics has the market capitalization of 93.05M
When is the next Outlook Therapeutics earnings date?▼
Outlook Therapeutics is going to release the next earnings report on December 18, 2026.
What were Outlook Therapeutics earnings last quarter?▼
41O.XETRA earnings for the last quarter are -0.08 EUR per share, whereas the estimation was -0.07 EUR resulting in a -12.5% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Outlook Therapeutics revenue for the last year?▼
Outlook Therapeutics revenue for the last year amounts to 1.2M EUR.
What is Outlook Therapeutics net income for the last year?▼
41O.XETRA net income for the last year is -54.48M EUR.
How many employees does Outlook Therapeutics have?▼
As of November 6, 2026, the company has 17 employees.
In which sector is Outlook Therapeutics located?▼
Outlook Therapeutics operates in the Health & Wellness sector.
When did Outlook Therapeutics complete a stock split?▼
The last stock split for Outlook Therapeutics was on March 14, 2024 with a ratio of 1:20.
Where is Outlook Therapeutics headquartered?▼
Outlook Therapeutics is headquartered in ISELIN, United States.